304 related articles for article (PubMed ID: 25813773)
1. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Tang A; Rabasa-Lhoret R; Castel H; Wartelle-Bladou C; Gilbert G; Massicotte-Tisluck K; Chartrand G; Olivié D; Julien AS; de Guise J; Soulez G; Chiasson JL
Diabetes Care; 2015 Jul; 38(7):1339-46. PubMed ID: 25813773
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
4. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
6. Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
Shan PF; Ji XL; Wang L; Li P; Ren YZ
Diabetes Care; 2015 Sep; 38(9):e148-9. PubMed ID: 26294784
[No Abstract] [Full Text] [Related]
7. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
[TBL] [Abstract][Full Text] [Related]
8. Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
Tang A; Rabasa-Lhoret R; Castel H; Wartelle-Bladou C; Gilbert G; Massicotte-Tisluck K; Chartrand G; Olivié D; Julien AS; de Guise J; Soulez G; Chiasson JL
Diabetes Care; 2015 Sep; 38(9):e150-1. PubMed ID: 26294785
[No Abstract] [Full Text] [Related]
9. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
[TBL] [Abstract][Full Text] [Related]
10. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
11. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
[TBL] [Abstract][Full Text] [Related]
12. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Wexler DJ; Krause-Steinrauf H; Crandall JP; Florez HJ; Hox SH; Kuhn A; Sood A; Underkofler C; Aroda VR;
Diabetes Care; 2019 Nov; 42(11):2098-2107. PubMed ID: 31391203
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
Harris SB; Kocsis G; Prager R; Ridge T; Chandarana K; Halladin N; Jabbour S
Diabetes Obes Metab; 2017 Jun; 19(6):858-865. PubMed ID: 28124817
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
[TBL] [Abstract][Full Text] [Related]
16. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
17. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
Aroda VR; Bailey TS; Cariou B; Kumar S; Leiter LA; Raskin P; Zacho J; Andersen TH; Philis-Tsimikas A
Diabetes Obes Metab; 2016 Jul; 18(7):663-70. PubMed ID: 26990378
[TBL] [Abstract][Full Text] [Related]
18. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
[TBL] [Abstract][Full Text] [Related]
20. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]